Biogen and Eisai Receive FDA Approval for LEQEMBI IQLIK™ Subcutaneous Injection as At-Home Maintenance Therapy for Early Alzheimer’s Disease
Biogen and Eisai have received FDA approval for LEQEMBI® IQLIK™, a subcutaneous injection for at-home maintenance treatment of early Alzheimer’s disease. This allows patients who completed 18 months of intravenous treatment to switch to a weekly injection or continue with monthly IV infusions. The approval aims to enhance access and reduce treatment burden for eligible patients in the U.S.
